Skip to main content
OpenTrials
Completed

NCT Number: NCT04042571

Permanent Cerebral Oxymetry Monitoring for Early Diagnosis and Treatment of Delayed Vasospasm After Subarachnoid Hemorrhage

Transcranial Doppler ultrasound (TCD) monitoring and CT-scanner perfusion are useful but imperfect tools to identify vasospasm and allow intervention to avoid infarction.

Permanent monitoring of cerebral tissue oximetry (rSO2) by NIRS, a noninvasive method could allow better vasospasm detection.

This study will evaluate diagnostic accuracy of cerebral oxymetry (NIRS) -by rSO2 measurement - in order to detect vasospasm in patient with severe subarachnoid hemorrhage compare to standard monitoring tools.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Bordeaux

Bordeaux, 33 076, France

About this study

Delayed vasospasm is a serious complication of aneurismal subarachnoid haemorhage (SAH) significantly influencing morbidity and mortality. Mostly observed between days 4 and 10 after aneurismal rupture, its incidence is higher in cases of severe SAH. Vasospasm strongly affects prognisis generating delayed cerebral ischemia.

Clinical deterioration (focal neurological deficit) is the best way to detect severe vasospasm. Unfortunately, most of severe SAH are intubated and sedated prohibiting neurological evaluation. In these frequent situations, Transcranial Doppler (TCD), clinical and biological monitoring, CT-scanner (angio-CT and Perfusion-CT), MRI and cerebral angiography are routinely used to detect vasospasm. Yet, these tools have imperfect sensitivity and specificty delaying diagnosis and treatment.

Near-InfraRed Spectroscopy (NIRS) is a non-invasive method measuring tissue oxygenation by regional saturation of capillary-oxygenated hemoglobin (rSO2). This technology demonstrated ability to measure cerebral oxygenation and has previously been reported to monitor carotid and pediatric surgery. To date a few studies also reported NIRS monitoring feasability in post-SAH vasospasm. Our aim is here to evaluate NIRS monitoring for the diagnosis of vasospasm in severe SAH.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women
  • Age ≥ 18 years
  • HSA of aneurysmal etiology less than 4 days before inclusion diagnosed by clinical presentation and emergency imaging
  • HSA "severe" defined according to the WFNS ≥ III
  • Intubated-ventilated patient or any other reason preventing a contributing neurological examination
  • Affiliate or beneficiary of a social security scheme
  • Free, informed and written consent signed by the representative

Exclusion criteria

  • Age <18 years
  • Significant vasospasm as soon as the detection was detected on the initial imaging
  • Possible Neurological Surveillance
  • Patient in limitation of active therapeutics or with high probability of soon limitation of active therapeutics
  • Intra-parenchymal frontal haematoma limiting the quality of measurement, diagnosed on imaging (Less than 25mm deep from the skin)
  • Patient in limitation of active therapeutics or with high probability of soon limitation of active therapeutics
  • Adhesive allergy to measuring patches
  • Patient under guardianship or safeguard of justice
  • Refusal of legal representative

Treatment and study plan

Cerebral oxymetry monitoring (NIRS)

Device

Near-InfraRed Spectroscopy (NIRS) is a non-invasive method measuring tissue oxygenation by regional saturation of capillary-oxygenated hemoglobin (rSO2). Starting on day 4 after aneurismal rupture NIRS electrods will be placed and maintained until day 12 permanently and blindly recording rSO2. Patients will be monitored following daily practice recommandations inclunding vasospasm detection and treatment.

Primary outcomes

  1. Permanent measurement of cerabral oxymetry (rSO2) by NIRS system

    Time frame: From day 4 to day 12 post aneurysmal subarachnoid hemorrhage

    Difference between NIRS basal measurement entre la mesure basale du NIRS (NIRS average on the first hour of recording respectively on the left and right) and the NIRS measurement during the follow-up (lowest mean NIRS observed over one hour in patients without vasospasm diagnosed by the reference test or mean NIRS observed over the hour.

Secondary outcomes

  1. Severity of angiographic spasm

    Time frame: Day 8 post aneurysmal subarachnoid hemorrhage

    Not significant (<50%) Significant (>50%) Severe.

  2. Pti02 value

    Time frame: Day 4 post aneurysmal subarachnoid hemorrhage

    Pti02 value (mm Hg)

  3. Pti02 value

    Time frame: Day 8 post aneurysmal subarachnoid hemorrhage

    Pti02 value (mm Hg)

  4. Pti02 value

    Time frame: Day 12 post aneurysmal subarachnoid hemorrhage

    Pti02 value (mm Hg)

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Acronym: COMOVA

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Aug 2, 2019
Registry last updated
Jun 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.